News
Novo, Wegovy and MAS
Digest more
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...
The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.
Health and Me on MSN19h
Wegovy Approved For MASH Treatment With Fibrosis But No Cirrhosis
FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...
The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...
Novo Nordisk makes the wildly popular GLP-1 drug semaglutide which it sells under the brand name Wegovy for weight-loss and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback